Article ; Online: Defining the natural history of rare genetic liver diseases: Lessons learned from the NAPPED initiative.
European journal of medical genetics
2021 Volume 64, Issue 7, Page(s) 104245
Abstract: While rare diseases collectively affect ~300 million people worldwide, the prevalence of each disease concerns a relatively small number of patients. Usually, only limited data with regard to natural history are available. Multicenter initiatives are ... ...
Abstract | While rare diseases collectively affect ~300 million people worldwide, the prevalence of each disease concerns a relatively small number of patients. Usually, only limited data with regard to natural history are available. Multicenter initiatives are needed to aggregate data and answer clinically relevant research questions. In 2017, we launched the NAtural course and Prognosis of PFIC and Effect of biliary Diversion (NAPPED) consortium. In three years, NAPPED created a global network focused on rare genetic liver diseases in the Progressive Familial Intrahepatic Cholestasis (PFIC) spectrum. During these years, we have learned important lessons which we feel should be taken into account when initiating and leading a global consortium. First, it is essential to 'keep it simple' from the start. Research questions, case report forms (CRFs) and data acquisition should be limited and clear to stay focused and keep the workload low for new participants. Secondly, early rewards and research output are needed to keep momentum and motivation. Quick output can only follow a clean and simple design. Thirdly, the leading team should be in touch and accessible. Ideally, an involved PhD-candidate is appointed as primary contact person. Lastly, be inclusive and actively involve all participants the consortium's course. Global consortia are critical for personalized medicine in rare diseases. Also, they are essential for setting up trials to investigate generic drugs and personalized therapies. We hope to herewith stimulate others that are starting (or are planning to start) a global consortium, ultimately to help improve the care for patients with a rare disease. |
---|---|
MeSH term(s) | Cholestasis, Intrahepatic/diagnosis ; Cholestasis, Intrahepatic/genetics ; Cholestasis, Intrahepatic/therapy ; Consensus ; Databases, Factual ; Genetic Diseases, Inborn/diagnosis ; Genetic Diseases, Inborn/genetics ; Genetic Diseases, Inborn/therapy ; Humans ; Practice Guidelines as Topic ; Rare Diseases/diagnosis ; Rare Diseases/genetics ; Rare Diseases/therapy |
Language | English |
Publishing date | 2021-05-13 |
Publishing country | Netherlands |
Document type | Journal Article |
ZDB-ID | 2184135-4 |
ISSN | 1878-0849 ; 1769-7212 |
ISSN (online) | 1878-0849 |
ISSN | 1769-7212 |
DOI | 10.1016/j.ejmg.2021.104245 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 84/9: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.